Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
(CSE:
QNTM
)
18.50
+1.00 (+5.71%)
Streaming Delayed Price
Updated: 2:58 PM EDT, May 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
23,856
Open
18.00
Bid (Size)
18.00 (100)
Ask (Size)
19.00 (100)
Prev. Close
17.50
Today's Range
18.00 - 19.60
52wk Range
3.900 - 25.64
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Finalizes $2.35 Million Settlement with Former CEO Raza Bokhari
Today 9:05 EDT
Via
Investor Brand Network
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
Today 7:00 EDT
Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years
From
Quantum BioPharma
Via
GlobeNewswire
Performance
YTD
+216.2%
+216.2%
1 Month
+93.7%
+93.7%
3 Month
+135.7%
+135.7%
6 Month
+148.3%
+148.3%
1 Year
+201.8%
+201.8%
More News
Read More
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
May 29, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
May 28, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets
May 21, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis
May 20, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
May 19, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
May 16, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
May 12, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
May 05, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time
April 24, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
April 22, 2025
From
Quantum BioPharma
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Issues Corporate Update
April 21, 2025
Via
Investor Brand Network
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario
April 14, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™
April 10, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
April 03, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis
April 01, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms
March 31, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
March 28, 2025
Via
ACCESS Newswire
Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
March 28, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors
March 27, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail Sales
March 26, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
March 20, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
February 26, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
February 18, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Frequently Asked Questions
Is QNTM publicly traded?
Yes, QNTM is publicly traded.
What exchange does QNTM trade on?
QNTM trades on the Canadian Securities Exchange
What is the ticker symbol for QNTM?
The ticker symbol for QNTM is QNTM on the Canadian Securities Exchange
What is the current price of QNTM?
The current price of QNTM is 18.50
When was QNTM last traded?
The last trade of QNTM was at 05/30/25 02:58 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.